Silence Therapeutics (SLN) Research & Development (2024 - 2026)
Silence Therapeutics (SLN) posted Research & Development of $9.1 million for Q1 2026, up 1415.28% sequentially from $602000.0 in Q4 2025, and down 56.17% YoY from $20.8 million in Q1 2025.
Silence Therapeutics (SLN) Research & Development (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported Research & Development for 3 years, with the latest figure at $9.1 million in Q1 2026.
- Quarterly Research & Development fell 56.17% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (down 66.0% YoY) and the FY2025 annual result came in at $4.8 million, down 92.94% from the prior year.
- Research & Development rose to $9.1 million in Q1 2026 per SLN's latest filing, from $602000.0 in the prior quarter.
- Over five years, Research & Development peaked at $40.2 million in Q4 2024 and troughed at $602000.0 in Q4 2025.
- A 3-year average of $10.5 million and a median of $7.8 million in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 3224.76% in 2025, down 98.5% in 2025.
- Over 3 years, Research & Development stood at $40.2 million in 2024, then tumbled by 98.5% to $602000.0 in 2025, then surged by 1415.28% to $9.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $9.1 million, $602000.0, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 9.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.15 Mn |
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 602,000.00 |
| Sep 30, 2025 | 13.15 Mn |
| Jun 30, 2025 | 936,000.00 |
| Mar 31, 2025 | 20.81 Mn |
| Dec 31, 2024 | 40.17 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 7.77 Mn |
| Mar 31, 2024 | 626,000.00 |